Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus intravesical BCG versus BCG alone for persistent or recurrent high-risk non-muscle-invasive bladder cancer after prior BCG
jRCT2031210118Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in bladder cancer, transitional cell carcinoma (TCC) and non-muscle-invasive bladder cancer (NMIBC) comparing Nivolumab + BCG with Placebo + BCG (2 arms). Primary endpoint: Event-free survival. Started May 2021; status: completed.
02
Drugs
nivolumabbcg vaccine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2031210118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210118.